Determination of tobramycin pharmacokinetics in burn patients to evaluate the potential utility of once-daily dosing in this population

Journal of Burn Care and Research

Volumn 35, Issue 4, 2014, Pages

  Vella, Diane ^a   Walker, Sandra A N ^a,b   Walker, Scott E ^a,b   Daneman, Nick ^a,c   Simor, Andrew ^a,c  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BODY WEIGHT; BURN PATIENT; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; STEADY STATE; BLOOD; BURN UNIT; BURNS; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; WOUND INFECTION; YOUNG ADULT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BURN UNITS; BURNS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TOBRAMYCIN; WOUND INFECTION; YOUNG ADULT;

EID: 84903816883     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e3182a226fb     Document Type: Article

References (30)

1. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev 2006;19:403-34.
2. Bloemsma GC, Dokter J, Boxma H, et al. Mortality and causes of death in a burn centre. Burns 2008;34:1103-07.
3. Mayhall CG. The epidemiology of burn wound infections: then and now. Clin Infect Dis 2003;37:543-50. (Pubitemid 37011779)
4. Altoparlak U, Erol S, Akcay MN, Celebi F, Kadanali A. The time-related changes of antimicrobial resistance patterns and predominant bacterial pro files of burn wounds and body flora of burned patients. Burns 2004;30:660-4. (Pubitemid 39314511)
5. Erol S, Altoparlak U, Akcay MN, Celebi F, Parlak M. Changes of microbial flora and wound colonization in burned patients. Burns 2004;30:357-61. (Pubitemid 38622449)
6. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult pat ients. Antimicrob Agents Chemother 1995;39:650-5.
7. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concen tration. J Infect Dis 1987;155:93-9. (Pubitemid 17225088)
8. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother 1997;39:677-86. (Pubitemid 27296406)
9. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999;44:319-27. (Pubitemid 29425682)
10. Zaske DE, Sawchuk RJ, Gerding D N, Strate RG. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976;16:824-8.
11. Loirat P, Rohan J, Baillet A, Beaufils F, David R, Chapman A. Increased gl omerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin. N Engl J Med 1978;299:915-9. (Pubitemid 9050457)
12. Bauer LA, Blouin RA. Influence of age on tobramycin pharmacokinetics in patients with normal renal function. Antimicrob Agents Chemother 1981;20:587-9. (Pubitemid 12168032)
13. Blanchet B, Jullien V, Vinsonneau C, Tod M. Influence of burns on pharmacokinetics and pharmacodynami cs of drugs used in the care of burn patients. Clin Pharmacokinet 2008;47:635-54.
14. Zaske DE, Cipolle RJ. Rapid individualization of gentamicin dosage regimens in 66 burn patients. Burns 1981;7:215-20. (Pubitemid 11178202)
15. Hollingsed TC,Harper DJ,Jennings JP,Morris SE,Saffle JR Aminoglycoside dosing in burn patients using first-dose pharmacokinetics J Trauma 1993 35 394-8. (Pubitemid 23292489)
16. Hoey LL, Tschida SJ, Rotschafer JC, Guay DR, Vance-Bryan K. Wide var iation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil 1997;18:116-24. (Pubitemid 27149235)
17. Prescott WA Jr., Nagel JL. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis. Pharmacotherapy 2010;30:95-08.
18. Smyth A, Tan K. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2006;3:CD002009.
19. Bracco D, Landry C, Dubois MJ, Eggimann P. Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns 2008;34:791-6.
20. Conil JM, Georges B, Breden A, et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 2006;28:226-30. (Pubitemid 44223987)
21. Zaske DE, Chin T, Kohls PR, Solem LD, Strate RG. Initial dosage regimens of gentamicin in patients with burns. J Burn Care Rehabil 1991;12:46-50.
22. Rutledge R, Lentz CW, Fakhry S, Hunt J. Appropriate use of the Glasgow Coma Scale in intubated patients: a linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scores. J Trauma 1996;41:514-22. (Pubitemid 26318084)
23. Meredith W, Rutledge R, Fakhry SM, Emery S, Kromhout-Schiro S. The conundrum of the Glasgow Coma Scale in intubated patients: a linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scor es. J Trauma 1998;44:839-44; discussion 844-5.
24. Nguyen A, Tailor SAN, Walker SE, et al. Utility of aminoglycoside (AMG) levels with once daily aminolgycoside (ODA) therapy [abstract]. Can J Hosp Pharm 1997;50:98.
25. Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111-8. (Pubitemid 38993688)
26. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN. Pathogen of occurrence and suscept ibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003;45:279-85. (Pubitemid 36555680)
27. Mathai D, Jo nes RN, Pfaller MA; SENTRY Participant Group North America. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (Nor th America). Diagn Microbiol Infect Dis 2001;40:129-36. (Pubitemid 32735552)
28. Akers KS, Cota JM, Frei CR, Chung KK, Mende K, Murray CK. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother 2011;55(10):4639-4 2.
29. Elligsen M, Walker SA, Walker SE, Simor A. Optimizing initial vancomycin dosing in burn patients. Burns 2011;37: 406-14.
30. Ansermino M, Hemsley C. Intens ive care management and control of infection. BMJ 2004;329:220- 3.pag e250-e257 (Pubitemid 39013283)